Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Benedict Benigno

Gynecologic Oncology Atlanta, GA Medical Doctor

NPI 1205802733 CMS profile 54755

980 Johnson Fy Rd Ne, Suite 130, Atlanta, GA 30342

Open in the dashboard

General payments

$272,812

269 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$330,570 paid to institutions, not to them · program years 2019–2020

Through program year 2021, Benedict Benigno of Atlanta, GA is reported in the CMS Open Payments database as having received $272,812 across 269 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $330,570 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Gynecologic Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $2,800 2
2020 General $30,354 30
2019 General $239,658 237

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Benedict Benigno
  • Gynecologic Oncology median
  • Middle half of Gynecologic Oncology
  • National median

In program year 2025, general payments to Benedict Benigno were reported at $0. Among 1,179 Gynecologic Oncology profiles paid that year, the median was $305 and the middle half received between $111 and $1,499.

Show as a table
Year Benedict Benigno Gynecologic Oncology median Middle half National median
2019 $239,658 $287 $113–$1,548 $163
2020 $30,354 $223 $59–$2,164 $114
2021 $2,800 $193 $68–$1,139 $132
2022 $0 $252 $90–$1,151 $149
2023 $0 $281 $102–$1,419 $160
2024 $0 $308 $108–$1,502 $164
2025 $0 $305 $111–$1,499 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. AstraZeneca Pharmaceuticals LP $162,722 123 payments
  2. Merck Sharp & Dohme Corporation $50,460 65 payments
  3. TESARO, Inc. $22,244 33 payments
  4. GlaxoSmithKline, LLC. $19,700 18 payments
  5. Clovis Oncology, Inc. $17,372 23 payments
  6. Boston Scientific Corporation $135 1 payment
  7. Puma Biotechnology, Inc. $78 1 payment
  8. Baxter Healthcare $38 1 payment
  9. Amgen Inc. $18 1 payment
  10. AbbVie, Inc. $15 1 payment
  11. Other $29 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $216,325 59 payments
  2. Travel and Lodging $35,704 96 payments
  3. Consulting Fee $13,090 3 payments
  4. Food and Beverage $7,682 110 payments
  5. Education $10 1 payment
Products named General payments · program years 2019–2021
  1. LYNPARZA Oncology $162,292 118 payments
  2. KEYTRUDA $49,989 59 payments
  3. ZEJULA Oncology $41,922 50 payments
  4. Rubraca $17,372 23 payments
  5. LYNPARZA Oncology $148 4 payments
  6. GENERAL GLOBAL ENDOMETRIAL ABLATION $135 1 payment
  7. NERLYNX $78 1 payment
  8. TISSEEL $38 1 payment
  9. ZEJULA Oncology $22 1 payment
  10. Neulasta $18 1 payment
  11. Other $44 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gynecologic Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record